Presentation Updates for 19th Annual Drug Discovery Summit

As the pharmaceutical industry faces increased pressures to lower costs, maintain pipelines and reduce clinical failures, innovation in strategies, techniques and technologies for drug discovery continue to push the industry forward. Join Oxford Global’s 19th Annual Drug Discovery Summit and co-located 6th Annual Discovery Chemistry & Drug Design Congress and Workshop to explore the latest innovations pushing industry to new heights.

 

Featuring high profile speakers from Eli Lilly, Merck and Amgen attendees will hear about:

 

• Establishing And Executing Option-Based Deals That Work For Both Parties    
  Anna Maroney, Vice President, Head of Alliance Management, AbbVie        
  
• Drug Discovery Approaches To Protein Misfolding And Aggregation Disease   
  Magnus Walter, Chief Scientific Officer Global Neurodegeneration, Eli Lilly   

• Early Dose Predictions - PKPD Relationships Impacting Medicinal Chemistry     
  Carl Petersson, Scientific Director Drug Disposition, Merck  
  
• The Confobody Technology, A New Platform To Enable Fragment Screening On GPCRs
  Christel Menet, Chief Scientific Officer, Confo Therapeutics  
  
• DNA-Encoded Library Technology Platforms: Yoctoreactor And Binder Trap Enrichment
  Nils Jakob Vest Hansen, Chief Executive Officer, Vipergen ApS     

 

New for 2018, the congress will also be covering critical areas such as:

 

• New modalities in drug discovery
• Artificial intelligence driven target identification
• DNA encoded libraries
• ADMET strategies in drug discovery
• Protein-Protein interactions – inhibition, modulation and stabilization
• Structure Based Drug Design of Kinase Inhibitors

 

View Agenda: http://bit.ly/2mqWK5m